“ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic Covid-19 in this interim analysis of ongoing clinical trials,” the Lancet said.from Industry-Economic Times
Read The Rest:economictimes...
“ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic Covid-19 in this interim analysis of ongoing clinical trials,” the Lancet said.from Industry-Economic Times
Read The Rest:economictimes...
